Literature DB >> 7639655

Anterior ischemic optic neuropathy secondary to interferon alfa.

V A Purvin1.   

Abstract

OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.
DESIGN: Description of the clinical findings in two patients with this condition.
SETTING: A neuro-ophthalmology referral center. PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.
INTERVENTIONS: Treatment with aspirin and prednisone in one patient. MAIN OUTCOME MEASURES: Visual acuity, color vision, Goldmann perimetry testing, and fundus photography.
RESULTS: Visual loss was mild and generally nonprogressive. The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon-associated vascular retinopathy.
CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa. The underlying pathogenesis is probably multifactorial.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7639655     DOI: 10.1001/archopht.1995.01100080093034

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  17 in total

1.  Pegylated interferon alpha-associated optic neuropathy.

Authors:  Kathleen T Berg; Bruce Nelson; Andrew R Harrison; Linda K McLoon; Michael S Lee
Journal:  J Neuroophthalmol       Date:  2010-06       Impact factor: 3.042

2.  Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yvette Leung; Stefan J Urbanski; Lynn Schindel; Robert P Myers
Journal:  Can J Gastroenterol       Date:  2006-10       Impact factor: 3.522

3.  Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.

Authors:  Bahram Bodaghi; Gael Gendron; Bertrand Wechsler; Céline Terrada; Nathalie Cassoux; Du Le Thi Huong; Claire Lemaitre; Christine Fradeau; Phuc LeHoang; Jean-Charles Piette
Journal:  Br J Ophthalmol       Date:  2006-10-18       Impact factor: 4.638

Review 4.  Ocular side effects of anti-rheumatic medications: what a rheumatologist should know.

Authors:  V Peponis; V C Kyttaris; S E Chalkiadakis; S Bonovas; N M Sitaras
Journal:  Lupus       Date:  2010-02-09       Impact factor: 2.911

Review 5.  [Janus-faced?: Effects and side-effects of interferon therapy in ophthalmology].

Authors:  N Stübiger; S Winterhalter; U Pleyer; D Doycheva; M Zierhut; C Deuter
Journal:  Ophthalmologe       Date:  2011-03       Impact factor: 1.059

6.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

7.  Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.

Authors:  I Kötter; A K Eckstein; N Stübiger; M Zierhut
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

8.  Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy.

Authors:  N R Miller; A C Arnold
Journal:  Eye (Lond)       Date:  2014-07-04       Impact factor: 3.775

Review 9.  Toxic optic neuropathy.

Authors:  Anat Kesler; Pazit Pianka
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

Review 10.  [Typical questions from the rheumatologist to the ophthalmologist and cooperating radiologist].

Authors:  B Nölle; M Both; M Heller; J B Roider
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.